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ABSTRACT  
  
Serum uric acid and cardiovascular disease   
 according to metabolic risk factors:       
the Korean Heart Study 
 
Eunjung Park  
Dept. of Public Health  
The Graduate School  
Yonsei University  
  
Background and Aims: The aims of this epidemiological study was to 
characterize the association between serum uric acid (SUA) levels and the incidence of 
cardiovascular disease (CVD) in a large, sample of the Korean general population without 
or and without metabolic risk factors. Given the correlation with hypertension, 
inflammation, endothelial dysfunction, insulin resistance, and obesity, uric acid has 
recently been proposed to play a role as a risk factor for CVD, but the evidence is 
discordant. However, most studies have examined the relation of CVD with 
hyperuricemia, or have focused upon populations with existing morbidity. 
ix 
 
Methods: The Korean Heart Study (KHS) enrolled 465,233 Korean adults who 
visited one of 18 health centers across the country between January1996 and December 
31, 2004. In this study, a total of 322,467 Koreans, without CVD in the KHS who had 
baseline, SUA measurements were analyzed. Metabolic risk factors were defined using 
the modified National Cholesterol Education Program-Adult Treatment Panel III criteria, 
except for waist circumference. All statistical tests were 2-sided, and statistical 
significance was accepted for p-values < 0.05. Hazard ratios and 95% confidence 
intervals for CVD events were determined according to SUA quintiles using multivariable 
Cox proportional hazard models. 
Results: The median follow-up was 9.5 years and we assessed the associations of 
SUA and CVD events (27,009 cases) after adjusting for potential confounders. Cox 
proportional hazards models were calculated to evaluate SUA by quintiles, as a predictive 
marker for CVD. SUA levels > 6.8mg/dL in men and > 4.8mg/dL in women were 
independently associated with an increased risk of CVD incidence; the adjusted hazard 
ratio (HR) for the highest versus lowest quintile of SUA was 1.22 (95% CI, 1.16-1.28) in 
men and 1.27 (95% CI, 1.19-1.35) in women. When stratified by conventional metabolic 
risk factors, SUA was significantly associated with ischemic heart disease (IHD) within 
CVD. However, in a subgroup analysis of participants without diabetes, the HR for IHD 
increased to 1.27 (95% CI, 1.14-1.41) in men and 1.51 (95% CI, 1.29-1.77) in women, 
and these findings showed a clear dose-response relationship. 
x 
 
Conclusions: Elevated serum uric acid levels were associated with IHD, 
independently of conventional CVD risk factors and metabolic syndrome. The increased 
risk of IHD associated with hyperuricemia was consistent across most subgroups. 
Hyperuricemia may increase the risk of IHD, particularly in females. Further research is 
needed to broadly evaluate the causal effects of multiple biomarkers on cardiovascular 
disease and metabolic risk traits using data from large-scale cohorts or GWAS including 
many different genetic variants. 
  
Keywords: Serum Uric Acid, Metabolic risk factor, Cardiovascular disease, Cohort study  
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I. INTRODUCTION  
  
Cardiovascular disease (CVD) is the leading cause of death worldwide and the 
second leading cause of death following malignant neoplasms and the utilization of 
medical institutions for CVD has increased sharply in Korea (Jo et al, 2016). 
High levels of uric acid, produced during the breakdown of purine, a substance 
found in many foods, has been traditionally implicated in the development of gout, 
kidney stones and kidney failure. Given its correlations with hypertension, inflammation, 
endothelial dysfunction, insulin resistance, dyslipidemia, and obesity, uric acid has 
recently been proposed to play a role as a risk factor for CVD, but the evidence is 
discordant (Kavous et al., 2012; Storhaug et al., 2013; Chuang et al., 2012; Zalawadiya et 
al., 2015). 
There is considerable documentation that serum uric acid (SUA) levels are 
correlated with many recognized cardiovascular risk factors, including age, male sex, 
hypertension, hypertriglyceridemia, obesity, insulin resistance, and consequently 
metabolic syndrome. Therefore, association observed between SUA elevations and CVD 
was long considered in terms of those correlations. However, recent evidence supports the 
possibility that hyperuricemia may be a significant and independent risk factor for 
hypertension and forms of CVDs, including ischemic heart disease (Bos et al., 2006; 
Krishnan et al., 2006; Holme et al., 2009; Li  et al., 2011; Ito et al., 2011; Chuang  et al., 
2012; Juraschek  et al., 2014; Lai et al., 2016). 
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Most studies have examined the relation of CVD with hyperuricemia, rather than 
uric acid levels in the normal range, or have focused upon populations with existing 
morbidity, including gout, hypertension, stroke, congestive heart failure, and/or diabetes. 
There is a notable paucity of general population-based studies. In the last few years, 
several meta-analyses of observational studies have found that hyperuricemia could 
significantly increase the risk of CVD events (Kim et al., 2010; Braga et al., 2016; Zuo et 
al., 2016; Li et al 2016). At present, the treatment of asymptomatic hyperuricemia is not 
considered beneficial or cost-effective, and generally is not recommended. Although 
recent studies on the relationship between hyperuricemia and the risk of CVD have been 
published, the results from cohort studies are still controversial. Furthermore, it remains 
unclear whether such risk factors modify the dose-response relationship between SUA 
level and CVD subtypes incidence.  
Moreover, it is not clear whether there are any metabolic risk factors effects between 
serum uric acid and CVD in men and women. Clarifying this potential sex-specific 
association has important public health implications to choose effective treatments for 
prevention of CVD.  
Therefore, we has to conduct this causal associate analysis of cohort study to 
determine whether sex modifies the association between SUA levels and risk of CVD and 
clarify the shape of the relationship between SUA and CVD. Additionally, we need to 
review published studies to clarify the associations between SUA levels and risk of CVD 
morbidity and mortality based on population studies. 
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II. OBJECTIVES  
  
 The objectives of this study was to characterize the association between SUA levels 
and the incidence of CVD in a large ample of the Korean general population with and 
without metabolic risk factors.  
 
The main aims of this study were as follows: 
1. To assess the association between SUA and metabolic risk factors  
2. To explore the association between SUA and cardiovascular disease  
3. To compare the association between SUA and IHD depending on the presence of 
metabolic risk factors 
4. To compare the association between SUA and CVD in women depending on 
menopausal status  
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III. MATERIALS AND METHODS  
  
A. Study population  
 
The Korean Chronic Disease Epidemiologic Study is a retrospective cohort study 
based on private health examinations. We collected data from examinations conducted at 
18 centers located in Korea. This study enrolled 465,233 Korean adults (284,232 men and 
181,001 women) who visited one of 18 health centers across the country between January 
1996 and December 31, 2004.  
The record linkage resulted in 430,920 study members (266,782 men and 164,138 
women) aged 30-74 years at the baseline health assessment. We have labeled this study as 
the Korean Heart Study (KHS) (Jee et al., 2014; Jee et al., 2014).  
All Koreans are members of the National Health Insurance Service (NHIS) and the 
record linkage for mortality was based on an official personal identification number. To 
ensure anonymity, all linkages were carried out by NHIS staff. 
For the current analyses, the exclusion criteria at baseline were as follows:  
1) History of cardiac problems, cerebral infarction, or cancer according to self-
report (19,762) 
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2) Missing values of age, SUA level, BMI, fasting blood glucose, blood 
pressure, lipid profile, creatinine, estimated cost of medical insurance, 
smoking history, or alcohol history (97,558) 
3) Currently taking diuretics or anti-gout drugs (107) 
4) Younger than 30 or older than 75 years old (25,339) 
The analytical sample therefore comprised 322,467 individuals (Figure 1).  
The Institutional Review Board of Human Research of Yonsei University approved 
the study (IRB approval number 4-2007-0065 and 4-2017-0186).  
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Figure 1. Flow chart describing the study population of the Korean Heart Study 
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B. Data collection  
  
The content of the health examination included a structured questionnaire containing 
questions about demographic characteristics, medical history, medication, and lifestyle 
factors (personal habits, smoking, drinking and physical activity).  A medical examination 
was also performed in which measurements of body weight, height, blood pressure, and 
fasting blood glucose were made.  
Minor differences might have been present in the health questionnaires since they 
were used by different health centers nationwide. However, the questionnaires were 
sorted and reorganized according to the needs of this study design. Depending on 
smoking, participants were categorized as nonsmokers, current smokers, and ex-smokers. 
Participants were classified according to alcohol consumption as alcohol drinkers and 
non-drinkers, and exercise habits were classified as exercise and no exercise. Additionally, 
education level, family history, past medical history, medication history, and for women, 
history of menarche and menopause were added as variables. 
The clinical tests included total cholesterol, triglycerides, high density lipoprotein 
(HDL) - cholesterol, low density lipoprotein (LDL) - cholesterol, and fasting blood 
glucose. LDL - cholesterol levels were measured using the Friedwald method or direct 
measurements depending on the health center. However, directly measured data were 
preferentially used when both types of measurement data had been collected. In addition, 
as a kidney function test, the glomerular filtration rate (GFR) was estimated by the 
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simplified Modification of Diet in Renal Disease equation, in which GFR 
(mL/min/1.73m2) = 186 × [PCr (mg/dL)] -1.154 × [age] -0.203 × [1.21] in black subjects, 
where PCr refers to plasma creatinine (National KF, 2002). 
Socioeconomic status was assessed using the amount of monthly deduction for 
health insurance that was estimated by the standards of the National Health Insurance 
Corporation (NHIC). These data were provided by the NHIC. 
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C. Outcome variables  
  
We identified participants with CVD from NHIC health insurance claim data. Deaths 
among subjects were confirmed by matching the information to the death records. Death 
certificates from the National Statistical Office were identified using the identification 
numbers assigned to the subjects at birth. 
The causes of death and the incidence of cardiovascular events were ascertained 
using the International Classification of Diseases-10th Revision codes (ICD-10). The 
accuracy rate of the ICD codes for cerebrovascular diseases in medical insurance claims 
for men in Korea was reported to be 83.0% in 2000 (Kimm et al., 2012). 
CVD was defined as the incidence of ischemic heart disease, hard coronary heart 
disease (CHD), or stroke. We divided the category of CVD into stroke and heart disease, 
which was in turn divided into ischemic heart disease and hard CHD. Ischemic heart 
disease was defined using the ICD-10 codes I20-I25, and hard CHD was defined as I21-
I24. 
Ischemic stroke, hemorrhagic stroke, and all stroke types were defined according to 
the following ICD-10 codes: ischemic stroke, I63-I639; hemorrhagic stroke, I60-I629; 
and all stroke types, I60-I699. 
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D. Statistical analysis  
  
Hazard ratios (HRs) and 95% confidence intervals (CIs) for CVD events were 
determined according to SUA quintiles using Cox proportional hazard models. 
Hyperuricemia was defined as a level ≥7.0 mg/dL in males and ≥6.5 mg/dL in females 
(Saggiani et al., 1996; Johnson et al., 1999). 
The multivariable Cox models included 2 models. One adjusted for age and sex and 
the other model adjusted for age, sex, body mass index (BMI), cholesterol, HDL 
cholesterol, GFR, diabetes, hypertension, cigarette smoking, alcohol consumption, and 
exercise. Stratifications by sex and SUA level were applied to the HRs with adjustment 
for age, BMI, total cholesterol, HDL cholesterol, diabetes, hypertension, cigarette 
smoking, alcohol consumption, and exercise. Additionally, stratification by conventional 
metabolic risk factors was also applied to the HRs, with adjustment for age, BMI, 
cholesterol, triglycerides, diabetes, hypertension, cigarette smoking, alcohol consumption, 
and exercise.  
All analyses were conducted using the SAS version 9.2 software package (SAS 
Institute Inc., Cary, NC, USA). All statistical tests were 2-sided, and statistical 
significance was accepted for p-values <0.05. 
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IV. RESULTS  
  
A. General characteristics of the study population  
  
Table 1 and 2 presents the baseline characteristics of the study participants, stratified 
by SUA quintile.  
In this study, the mean age of the 322,467 participants was 44.61 (standard deviation 
[SD], 9.37) years in men, and 46.86 (SD, 1.06) years in women. The mean SUA level was 
5.84 (SD, 1.23) mg/dL in men and 4.10 (SD, 0.91) mg/dL in women, and was 
significantly higher in men than in women. In additional, hyperuricemia was associated 
with sex, and the prevalence of hyperuricemia was 17.1% in men and 1.31% in women. 
The mean GFR was 82.57 (SD, 13.10) mL/min/1.73 m2 in men and 82.85 (SD, 15.04) 
mL/min/1.73 m2 in women. Levels of SUA significantly increased with age, weight, 
height, creatinine, and GFR (p for trend <0.05) in both men and women. However, SUA 
did not show a statistically significant association with the amount of the monthly 
deduction for health insurance (Table 1, Table 2).  
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B. Associations between serum uric acid and metabolic risk factors  
The relationships of fasting SUA quintiles with metabolic and socioeconomic risk 
factors were assessed in the Korean population. In men, levels of SUA significantly 
increased with age, weight, height, BMI, systolic blood pressure, diastolic blood pressure, 
total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides (p for trend <0.05). 
However, SUA did not show a statistically significant relationship with fasting blood 
glucose (Table 1). Similar results were obtained in women (Table 2).  
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Table 1. Baseline characteristics of study participants from the Korean Heart Study according to serum 
uric acid levels in men  
(N=204,295)  
 Mean (SD) 
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
P for trend ≤ 4.9mg/dL 4.9-5.5mg/dL 5.5-6.1mg/dL 6.1-6.8 mg/dL ≥6.8mg/dL 
40,558 36,505 42,585 41,247 43,400 
Age (years) 44.61 (9.37) 46.78   (9.78) 45.24 (9.36) 44.35 (9.17) 43.68 (9.02) 43.19 (9.11) 0.0054 
Serum uric acid 
(mg/dL) 5.84 (1.23) 4.18   (0.57) 5.16 (0.17) 5.75 (0.17) 6.38 (0.20) 7.55 (0.74) 0.0008 
Weight (kg) 69.24 (9.45) 66.18   (9.19) 67.57 (8.97) 68.96 (8.99) 70.45 (9.09) 72.61 (9.57) 0.0004 
Height (cm) 169.95 (5.72) 169.31   (5.81) 169.78 (5.71) 170.04 (5.68) 170.22 (5.67) 170.35 (5.70) 0.0072 
Body mass index 
(kg/m2) 23.94 (2.81) 23.06   (2.76) 23.42 (2.71) 23.83 (2.69) 24.29 (2.67) 24.99 (2.78) 0.0012 
Fasting blood  
glucose (mg/dL) 95.83 (22.84) 101.53  (34.79) 95.67 (22.54) 94.26 (18.73) 93.80 (16.96) 94.09 (15.47) 0.0904 
Systolic blood 
pressure (mmHg) 122.24 (16.12) 121.29  (16.34) 121.07 (15.88) 121.69 (15.97) 122.49 (15.84) 124.43 (16.28) 0.0410 
Diastolic blood 
pressure (mmHg) 77.71 (11.45) 76.55  (11.33) 76.70 (11.20) 77.36 (11.34) 78.12 (11.36) 79.58 (11.70) 0.0111 
Serum total 
cholesterol (mg/dL) 193.30 (34.99) 187.66  (33.50) 189.62 (33.00) 192.15 (33.14) 195.14 (33.67) 201.05 (34.83) 0.0048 
High-density 
lipoprotein 
cholesterol (mg/dL) 
48.15 (9.94) 49.43  (10.73) 48.87 (10.26) 48.18 ( 9.77) 47.63 ( 9.48) 46.82 ( 9.27) <0.0001 
Low-density 
lipoprotein 
cholesterol (mg/dL) 
116.82 (32.16) 113.61  (30.97) 115.20 (31.05) 116.57 (31.46) 117.97 (32.48) 120.35 (34.07) 0.0007 
Triglyceride (mg/dL) 153.42 (92.40) 132.93  (79.60) 138.12 (80.67) 147.98 (85.90) 159.71 (92.12) 184.79(108.85) 0.0094 
Creatinine (mg/dL) 1.06 (0.17)  1.02  ( 0.15) 1.04 ( 0.14) 1.06 ( 0.14) 1.07 ( 0.15) 1.11 ( 0.25) 0.0036 
Glomerular filtration 
rate(mL/min/1.73 m2) 82.57 (13.10) 85.66  (13.58) 84.99 (12.90) 82.80 (12.62) 81.63 (12.68) 79.16 (12.83) 0.0012 
Amount of monthly 
deduction for health 
insurance (won) 
153,819.42 
(144,243.59) 
148,8636.50 
(13,9287.01) 
154,405.27
(144,598.22)
155,153.84
(145,674.85)
155,493.71
(145,482.41)
155,269.58
(145,791.30) 0.1089 
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Table 2. Baseline characteristics of study participants from the Korean Heart Study according to serum 
uric acid levels in women 
(N=118,172) 
 Mean (SD) 
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
P for trend  ≤3.4mg/dL  3.4-3.8mg/dL  3.8-4.3mg/dL  4.3-4.8mg/dL   ≥4.8mg/dL 
23,593 19,913 27,496 22,022 25,148 
Age (years) 46.86 (10.06) 45.61 (9.56) 45.71 (9.65) 46.26 (9.88) 47.20 (10.17) 49.31 (10.50) 0.0230 
Serum uric acid 
(mg/dL) 4.10 (0.91) 2.92 (0.37) 3.56 (0.11) 4.00 (0.14) 4.47 (0.14) 5.39 (0.62) 0.0011 
Weight (kg) 56.97 (7.81) 55.03 (7.10) 55.68 (7.21) 56.51 (7.47) 57.61 (7.69) 59.77 (8.48) 0.0067 
Height (cm) 156.97 (5.35) 157.19 (5.34) 157.28 (5.32) 157.11 (5.33) 156.92 (5.32) 156.46 (5.40) 0.0479 
Body mass index 
(kg/m2) 23.14 (3.09) 22.29 (2.79) 22.54 (2.83) 22.91 (2.94) 23.41 (3.05) 24.43 (3.32) 0.0089 
Fasting blood  
glucose (mg/dL) 92.78 (19.63) 93.22 (25.22) 91.65 (19.79) 91.88 (17.80) 92.47 (17.12) 94.53 (17.19) 0.0429 
Systolic blood 
pressure (mmHg) 118.78 (19.09) 116.29 (17.87) 116.63 (18.20) 117.88 (18.37) 119.43 (19.41) 123.26 (20.53) 0.0202 
Diastolic blood 
pressure (mmHg) 73.63 (11.87) 72.15 (11.34) 72.38 (11.45) 73.19 (11.63) 74.14 (11.91) 76.03 (12.49) 0.0114 
Serum total 
cholesterol (mg/dL) 192.90 (36.69) 184.70 (34.46) 187.55 (34.32) 191.15 (35.69) 195.98 (36.58) 204.06 (38.63) 0.0041 
High-density 
lipoprotein 
cholesterol (mg/dL) 
55.37 (12.56) 57.05 (12.65) 56.38 (12.55) 55.78 (12.57) 54.69 (12.38) 52.98 (12.25) 0.0058 
Low-density 
lipoprotein 
cholesterol (mg/dL) 
117.19 (33.48) 110.04 (31.17) 112.93 (31.17) 115.80 (32.73) 119.89 (33.48) 126.75 (35.72) 0.0028 
Triglyceride (mg/dL) 111.45 (67.54) 96.65 (54.17) 99.99 (56.46) 106.94 (61.63) 116.83 (70.65) 134.63 (82.13) 0.0106 
Creatinine (mg/dL) 0.81 (0.14) 0.78 ( 0.11) 0.80 (0.11) 0.81 (0.11) 0.82 (0.12) 0.85 (0.19) 0.0030 
Glomerular filtration 
rate(mL/min/1.73 m2) 82.85 (15.04) 87.94 (15.17) 85.00 (14.77) 83.39 (14.60) 81.31 (14.25) 78.07 (14.81) 0.0009 
Amount of monthly 
deduction for health 
insurance (won) 
140099.55
(136,015.43)
139,433.28 
(133,157.98) 
141,398.73
(137,5341.92)
141,330.43
(140,956.88)
139,613.25
 (133,445.51)
138,775.95
(134,321.32)
0.5659 
15 
C. Associations between serum uric acid and cardiovascular disease 
The KHS included 322,467 Korean adults with complete data on SUA and correlated 
variables who were retrospectively followed up for 9.5 years, with a total time at risk of 
2,856,996 person-years.  
The total CVD events comprised 27,009 cases in men (Table 3) and women (Table 
4). In men, there were 3811 total cases of stroke, 2181 of ischemic stroke, 840 of 
hemorrhagic stroke, 6347 of ischemic heart disease, and 1197 of hard CHD. In women, 
there were 2533 total cases of stroke, 1343 of ischemic stroke, 561 of hemorrhagic stroke, 
2865 of ischemic heart disease, and 308 of hard coronary heart disease.  
In the Cox proportional hazards models adjusted for age, BMI, cholesterol, HDL 
cholesterol, GFR, diabetes, hypertension, cigarette smoking, alcohol consumption, and 
exercise, high SUA levels were positively related to the risk of total CVD in men (p for 
trend <0.0442) and in women (p for trend <0.0297). 
The HR for total CVD was statistically significant, and the HR for ischemic heart 
disease in men with highest quintile of SUA was 1.17 (95% CI, 1.08-1.26) compared to 
those with the lowest quintile of SUA (p for trend=0.0542). However, there was no 
independent association between SUA and stroke. In men, the HRs of the highest versus 
the lowest quintile of SUA were 1.05 (95% CI, 0.95-1.16) for stroke and 1.05 (95% CI, 
0.93-1.20) for ischemic stroke. No association was found between hyperuricemia and 
stroke in men (Table 3).   
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In women, the HRs (95% CI) of the highest versus the lowest quintile of SUA was 
1.27 (1.19-1.35) for total CVD events, and a dose-response relationship also appeared 
among SUA quintiles (p for trend = 0.0297). Compared with the first SUA quartile, the 
HRs for incident ischemic heart disease in the second, third, fourth and fifth SUA 
quintiles in women were 1.12 (95% CI, 0.98-1.28), 1.07 (95% CI, 0.94-1.22), 1.14 (95% 
CI, 1.00-1.29) and 1.34 (95% CI, 1.19-1.51), respectively (p for trend <0.0310) in the 
fully adjusted model. The HRs of the highest versus lowest quintiles of SUA were 1.05 
(95% CI, 0.93-1.18) for stroke and 1.09 (95% CI, 0.92-1.28) for ischemic stroke in 
women. Nonetheless, there was no independent association between hyperuricemia and 
hemorrhagic stroke in women (Table 4).  
Men with hyperuricemia had a 1.21-fold increase in the risk of CVD and a 1.16-fold 
increase in risk of ischemic heart disease, and women with hyperuricemia had a 1.58-fold 
increase in the risk of CVD and 1.36-fold increase in the risk of ischemic heart disease 
(Figure 1). 
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Table 3. Hazard ratios (95% confidence intervals) for the relationship of serum uric acid with 
cardiovascular disease incidence in men 
 (N=204,295) 
Hazard ratios (HRs) were adjusted for age, sex, body mass index, cholesterol, high-density lipoprotein cholesterol, diabetes, hypertension, cigarette 
smoking status (ex/never/current), and alcohol consumption, and were stratified by sex. Rates are age-standardized incidence rates per 100,000. 
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; IHD, ischemic heart disease; SD, standard deviation.  
Hyperuricemia was defined as a serum uric acid level of ≥7.0 mg/dL in men or ≥6.5 mg/dL in women.
Types of CVD 
Quintile 1 
(40,558) 
Quintile  2 
(36,505) 
Quintile  3 
(42,585) 
Quintile  4 
(41,585) 
Quintile  5 
(41,247) P  for 
 trend 
HRs (95%CI) 
of  hyperuricemia 
HRs  (95%CI) 
1-SD increased 
≤ 4.9mg/dL 4.9-5.5mg/dL 5.5-6.1mg/dL 6.1-6.8 mg/dL ≥6.8 mg/dL ≥7.0 mg/dL per 1mg/dL 
Total  
CVD 
Case 2,494 1,958 2,109 2,098 2,389 
0.0442 
1,969 11,048 
Rate 707 693 692 743 861 1.21 
(1.16-1.26) 
1.06 
(1.05-1.08) HR 1.00 0.99 (0.95-1.05) 
1.03 
(0.98-1.08) 
1.10 
(1.05-1.16) 
1.22 
(1.16-1.28) 
IHD 
Case 1,350 1,154 1,238 1,222 1,403 
0.0542 
1,181 6,367 
Rate 372 394 392 422 488 1.16 
(1.09-1.24) 
1.07 
(1.04-1.09) HR 1.00 1.08 (0.99-1.17) 
1.03 
(0.95-1.11) 
1.10 
(1.01-1.19) 
1.17 
(1.08-1.26) 
Total stroke 
Case 929 643 724 682 771 
0.2626
612 3,749 
Rate 273 245 257 258 301 1.06 
(0.97-1.15) 
1.02 
(0.98-1.05) HR 1.00 0.91 (0.83-1.01) 
0.96 
(0.87-1.05) 
0.97 
(0.87-1.07) 
1.05 
(0.95-1.16) 
Ischemic 
stroke 
Case 584 399 432 394 477 
0.6388
383 2,286 
Rate 174 160 163 151 194 1.05 
(0.94-1.18) 
1.02 
(0.97-1.06) HR 1.00 0.95 (0.84-1.09) 
0.98 
(0.86-1.11) 
0.98 
(0.86-1.12) 
1.05 
(0.93-1.20) 
Hemorrhagic 
stroke 
Case 203 136 165 167 169 
0.1089
126 840 
Rate 61 49 53 63 65 1.00 
(0.83-1.22) 
1.02 
(0.96-1.09) HR 1.00 0.78 (0.63-0.97) 
0.95 
(0.78-1.16) 
0.95 
(0.77-1.17) 
0.96 
(0.78-1.18) 
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Table 4. Hazard ratios (95% confidence intervals) for the relationship of serum uric acid with 
cardiovascular disease incidence in women 
(N=122,639) 
Hazard ratios (HRs) were adjusted for age, sex, body mass index, cholesterol, high-density lipoprotein cholesterol, diabetes, hypertension, cigarette 
smoking status (ex/never/current), and alcohol consumption, and were stratified by sex. Rates are age-standardized incidence rates per 100,000. 
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; IHD, ischemic heart disease; SD, standard deviation.   
Hyperuricemia was defined as a serum uric acid level of ≥7.0 mg/dL in men or ≥6.5 mg/dL in women.  
 
Types of CVD 
Quintile 1 
(24,474) 
Quintile  2 
(20,587) 
Quintile  3 
(28,481) 
Quintile  4 
(22,807) 
Quintile  5 
(26,290) P  for 
 trend 
HRs (95%CI) 
of  hyperuricemia 
HRs  (95%CI) 
1-SD increased 
≤3.4mg/dL 3.4-3.8mg/dL 3.8-4.3mg/dL 4.3-4.8mg/dL ≥4.8mg/dL ≥6.5 mg/dL per 1mg/dL 
Total 
CVD 
Case 885 822 1207 1132 1864 
0.0297 
302 5,910 
Rate 742 744 763 838 1017 1.58 
(1.42-1.76) 
1.11 
(1.09-1.13) HR 1.00 1.04 (0.97-1.12) 
1.03 
(0.97-1.10) 
1.10 
(1.03-1.18) 
1.27 
(1.19-1.35) 
IHD 
Case 358 357 530 520 843 
0.0310 
82 2,608 
Rate 282 308 328 401 445 1.36 
(1.10-1.68) 
1.11 
(1.07-1.15) HR 1.00 1.12 (0.98-1.28) 
1.07 
(0.94-1.22) 
1.14 
(1.00-1.29) 
1.34 
(1.19-1.51) 
Total 
stroke 
Case 385 332 499 445 734 
0.1081 
71 2,395 
Rate 336 319 330 326 432 1.38 
(1.10-1.72) 
1.04 
(1.00-1.08) HR 1.00 0.95 (0.82-1.09) 
0.95 
(0.84-1.08) 
0.97 
(0.85-1.11) 
1.05 
(0.93-1.18) 
Ischemic 
stroke 
Case 203 172 265 230 417 
0.2354 
40 1,287 
Rate 94 96 108 118 188 1.44 
(1.09-1.91) 
1.06 
(1.01-1.11) HR 1.00 0.92 (0.75-1.12) 
0.95 
(0.76-1.13) 
0.90 
(0.75-1.08) 
1.09 
(0.92-1.28) 
Hemorrhagic 
stroke 
Case 86 86 107 107 167 
0.2921 
20 553 
Rate 40 48 43 55 75    1.21 
(0.72-2.03) 
   1.06 
(0.98-1.14) HR 1.00 1.09 (0.81-1.46) 
1.00 
(0.76-1.32) 
1.17 
(0.89-1.55) 
1.18 
(0.91-1.54) 
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Hazard ratios (HRs) were adjusted for age, sex, body mass index, cholesterol, high density 
lipoprotein cholesterol, diabetes, hypertension, cigarette smoking status (ex/never/current), and 
alcohol consumption, and were stratified by sex.  
ASCVD = atherosclerotic cardiovascular disease; IHD = ischemic heart disease.  
Hyperuricemia was defined as a serum uric acid level of ≥7.0 mg/dL in men or ≥6.5 mg/dL in 
women. 
 
Figure 2. Hazard ratios of all forms of cardiovascular diseases according to 
hyperuricemia. 
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D. Serum uric acid and ischemic heart disease with or 
without metabolic risk factors 
The association between serum uric acid and ischemic heart disease with or without 
metabolic risk factors was evaluated in Korean men and women. In both genders, those 
without diabetes, hypertension, hyperlipidemia or obesity-related risk factors had higher 
HRs for the incidence of CVD associated with SUA than those with such factors. 
Additionally, in the absence of metabolic risk factors, compared to those in the lowest 
quartile of SUA, participants in the fourth and fifth SUA quintiles had a significantly 
increased risk of ischemic heart disease.  
However, with an increase of 1 mg/dL of SUA, the incidence of ischemic heart 
disease in men with normal HDL cholesterol and low HDL cholesterol increased, but not 
significantly [normal HDL cholesterol: HR = 1.10 (95% CI, 1.06-1.13); low HDL 
cholesterol: HR  = 1.03 (95% CI, 0.98-1.08)] (Supplementary Figure 1, Supplementary 
Figure 2). In the relationship of SUA with the incidence of ischemic heart disease 
according to each metabolic risk factor, the HRs for the incidence of ischemic heart 
disease significantly increased with increases of 1 mg/dL of SUA in the presence of each 
metabolic risk factor in both men and women. In women, with an increase of 1 mg/dL of 
SUA, the HRs for incidence of ischemic heart disease among those with and without 
diabetes increased to the greatest extent [with diabetes: HR = 1.15 (95% CI, 1.09-1.20); 
without diabetes: HR= 1.08 (95% CI, 1.02-1.14)]. 
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1. Diabetes  
In men with diabetes, the HR of the highest versus the lowest quintile of SUA was 
0.97 (95% CI, 0.87-1.09) for ischemic heart disease events, and was not statistically 
significant (Figure 4). However, in men without diabetes, the HR of the highest versus the 
lowest quintile of SUA was 1.24 (95% CI, 1.11-1.38). The highest quintile of SUA 
showed a significantly greater risk of ischemic heart disease incidence in the absence of 
diabetes. Additionally, a dose-response relationship also appeared among the SUA 
quintiles in men (Figure 3). 
In women without diabetes, compared with the first SUA quartile, the HRs for 
ischemic heart disease incidence in the second, third, fourth and fifth SUA quintiles were 
1.13 (95% CI, 0.94-1.36), 1.18 (95% CI, 1.00-1.40), 1.26 (95% CI, 1.07-1.50) and 1.52 
(95% CI, 1.29-1.78), in the fully adjusted model, and a dose-response relationship also 
appeared among SUA quintiles (Figure 5). In women with diabetes, the HR of the highest 
versus the lowest quintile of SUA was 1.16 (95% CI, 0.94-1.43) for ischemic heart 
disease events, and was not statistically significant (Figure 6). 
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Figure 3. Hazard ratios of ischemic heart disease incidence in the study population without 
diabetes according to serum uric acid levels in men. 
 
Figure 4. Hazard ratios of ischemic heart disease incidence in the study population with 
diabetes according to serum uric acid levels in men. 
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Figure 5. Hazard ratios of ischemic heart disease incidence in the study population without 
diabetes according to serum uric acid levels in women. 
 
Figure 6. Hazard ratios of ischemic heart disease incidence in the study population with 
diabetes according to serum uric acid levels in women. 
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2. Hypertension 
In men without hypertension, the HR of the highest versus the lowest quintile of 
SUA was 1.21 (95% CI, 1.08-1.37) for ischemic heart disease events (Figure 7). In men 
with hypertension, the HR of the highest versus the lowest quintile of SUA was 1.15 
(95% CI, 1.03-1.28) for ischemic heart disease events (Figure 8). 
In women without hypertension, compared with the first SUA quartile, the HRs for 
ischemic heart disease incidence in the second, third, fourth and fifth SUA quintiles were 
1.10 (95% CI, 0.98-1.23), 1.08 (95% CI, 0.97-1.21), 1.04 (95% CI, 0.93-1.16) and 1.15 
(95% CI, 1.03-1.28) in the fully adjusted model, and a dose-response relationship 
appeared among SUA quintiles (Figure 9). Women with hypertension also showed similar 
results (Figure 10). 
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Figure 7. Hazard ratios of ischemic heart disease incidence in the study population without 
hypertension according to serum uric acid levels in men. 
 
Figure 8. Hazard ratios of ischemic heart disease incidence in the study population with 
hypertension according to serum uric acid levels in men. 
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Figure 9. Hazard ratios of ischemic heart disease incidence in the study population without 
hypertension according to serum uric acid levels in women. 
 
Figure 10. Hazard ratios of ischemic heart disease incidence in the study population with 
hypertension according to serum uric acid levels in women. 
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3. Dyslipidemia 
In men with dyslipidemia, the HR of the highest versus the lowest quintile of SUA 
was 1.02 (95% CI, 0.88-1.19) for ischemic heart disease events (Figure 12). Additionally, 
in the absence of dyslipidemia, the HR of the highest versus the lowest quintile of SUA 
was 1.27 (95% CI, 1.16-1.39) for ischemic heart disease events, and a dose-response 
relationship appeared among SUA quintiles (Figure 11). 
In women without dyslipidemia, compared with the first SUA quartile, the HRs for 
ischemic heart disease incidence in the second, third, fourth and fifth SUA quintiles were 
1.21 (95% CI, 0.99-1.47), 1.19 (95% CI, 0.99-1.43), 1.30 (95% CI, 1.08-1.56), and 1.51 
(95% CI, 1.26-1.80) in the fully adjusted model, and a dose-response relationship 
appeared among SUA quintiles (Figure 13). Women with dyslipidemia showed similar 
results (Figure 14). 
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Figure 11. Hazard ratios of ischemic heart disease incidence in the study population without 
dyslipidemia according to serum uric acid levels in men. 
 
Figure 12. Hazard ratios of ischemic heart disease incidence in the study population with 
dyslipidemia according to serum uric acid levels in men. 
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Figure 13. Hazard ratios of ischemic heart disease incidence in the study population without 
dyslipidemia according to serum uric acid levels in women. 
 
Figure 14. Hazard ratios of ischemic heart disease incidence in the study population with 
dyslipidemia according to serum uric acid levels in women. 
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4. Obesity 
In men with obesity, the HR of the highest versus the lowest quintile of SUA was 
1.05 (95% CI, 0.93-1.18) for ischemic heart disease events and was not statistically 
significant (Figure 16). Additionally, in the absence of obesity, the HR of the highest 
versus the lowest quintile of SUA was 1.19 (95% CI, 1.07-1.32). The group with the 
highest quintile of SUA had a significantly greater risk of ischemic heart disease 
incidence (Figure 15). 
In women without obesity, compared with the first SUA quartile, the HRs for 
ischemic heart disease incidence in the second, third, fourth and fifth SUA quintiles were 
1.28 (95% CI, 1.07-1.54), 1.21 (95% CI, 1.02-1.43), 1.32 (95% CI, 1.11-1.57), and 1.45 
(95% CI, 1.22-1.71) in the fully adjusted model, and a dose-response relationship 
appeared among SUA quintiles (Figure 17). Women with dyslipidemia showed similar 
results (Figure 18). 
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Figure 15. Hazard ratios of ischemic heart disease incidence in the study population without 
obesity according to serum uric acid levels in men. 
 
Figure 16. Hazard ratios of ischemic heart disease incidence in the study population with 
obesity according to serum uric acid levels in men. 
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Figure 17. Hazard ratios of ischemic heart disease incidence in the study population without 
obesity according to serum uric acid levels in women. 
 
Figure 18. Hazard ratios of ischemic heart disease incidence in the study population with 
obesity according to serum uric acid levels in women. 
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5. Menopausal status in women 
We determined the HRs for all forms of cardiovascular disease by menopausal status 
and SUA quintile. The adjusted HRs for incidence significantly increased as SUA levels 
increased in women. For the HRs for atherosclerotic cardiovascular disease and ischemic 
heart disease according to SUA quintiles, the menopause-specific patterns similarly 
showed slight dose-response curves in women regardless of menopausal status. 
As shown in Figure 19, the non-menopausal group with highest quintile of SUA had 
a significantly greater risk of all forms of CVD than the menopause group with the 
highest quintile of SUA.  
In particular, for total stroke and ischemic stroke, a difference in the curve was found 
among those with metabolic risk factors according to SUA quintile. The menopause 
group had flat curves, whereas the women who had not undergone menopause showed 
dose-response curves (Figure 23). 
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Figure 19. Hazard ratios of ASCVD incidence in subjects with menopause according to 
serum uric acid levels. ASCVD, atherosclerotic cardiovascular disease. 
 
Figure 20. Hazard ratios of ASCVD incidence in the subjects without menopause according 
to serum uric acid levels. ASCVD, atherosclerotic cardiovascular disease. 
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Figure 21. Hazard ratios of ischemic heart diseases incidence in subjects with menopause 
according to serum uric acid levels. 
 
Figure 22. Hazard ratios of ischemic heart diseases incidence in subjects without menopause 
according to serum uric acid levels. 
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Figure 23. Hazard ratios of stroke incidence in subjects with menopause according to serum 
uric acid levels. 
 
Figure 24. Hazard ratios of stroke incidence in subjects without menopause according to 
serum uric acid levels. 
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Figure 25. Hazard ratios of ischemic stroke incidence in subjects with menopause according 
to serum uric acid levels. 
 
Figure 26. Hazard ratios of ischemic stroke incidence in subjects without menopause 
according to serum uric acid levels. 
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V. DISCUSSION  
  
In the KHS, the highest quintile of SUA levels was associated with an increase in the 
risk of subsequently developing ischemic heart disease among 332,462 healthy adults 
without CVD at baseline. We also found that the risk for ischemic heart disease associated 
with SUA was significantly greater in adults without metabolic risk factors in the highest 
SUA quintile. In particular, there was a clear dose-response relationship between SUA 
and ischemic heart disease incidence in subjects without diabetes. Furthermore, in our 
subgroup analysis of menopausal and non-menopausal women, there was a positive 
association between SUA levels and CVD in the pre-menopausal group. However, in 
menopausal group, there was no relationship between SUA and CVD, especially stroke 
In the KHS, we found SUA levels to be a predictor of total CVD events with or 
without hypertension and diabetes, as was recently reported in a cohort study from 
Taiwan (Chen et al., 2009).  
Our data provided an angle to examine the connection between hyperuricemia and 
the components of metabolic syndrome. In addition to providing general findings for the 
healthy population, we demonstrated a significant risk associated with elevated SUA 
levels for ischemic heart disease in a subgroup with low metabolic risk factors. This result 
may further support the proposal that hyperuricemia poses a risk for the development of 
ischemic heart disease in the general population without metabolic risk factors.  
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1. Relationship between SUA and metabolic risk factors 
 
Despite the association of hyperuricemia with cardiovascular risk factors, it remains 
controversial whether SUA is an independent predictor of cardiovascular disease.  
Considerable evidence suggests that SUA levels are associated with many 
cardiovascular risk factors, including age, male sexual function, hypertension, 
hypertriglyceridemia, obesity, insulin resistance and, consequently, metabolic syndrome. 
Several studies have suggested that hyperuricemia has a pathogenic role and 
predictive value in the development of hypertension. Therefore, a causal link to the 
development of hypertension is a plausible explanation for the possible increased 
cardiovascular risk in patients with hyperuricemia (Baker et al., 2005; Zuo et al., 2016). 
Hyperuricemia is frequently encountered in hypertensive patients. Having hyperuricemia 
and hypertension is associated with a 3- to 5-fold increase in CHD compared to patients 
with normal SUA levels (Alderman et al., 2004). The Losartan Intervention for Endpoint 
Reduction in Hypertension study was the first to demonstrate that reducing SUA levels 
was associated with a reduction of cardiovascular events in hypertensive patients (Dahlof 
et al., 2002). 
Numerous studies have shown that hyperlipidemia is traditional cardiovascular risk 
factor and increases the risk of cardiovascular events (Verdecchia et al 2000, Puddu et al 
2001). Increased SUA levels may encourage lipid peroxidation and promote the oxidation 
of LDL cholesterol, which may play a role in the development of atherosclerosis and 
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would also explain its association with CHD (Gomez et al., 2014; Zuo et al., 2016). 
Because human atherosclerosis plaques contain more uric acid than normal artery walls, 
researchers have proposed that SUA may play a direct role in the atherosclerosis process 
(Zuo et al., 2016). Increased SUA concentrations may be associated with the increasing 
prevalence of insulin resistance, abdominal obesity, hyperlipidemia, and hypertension. 
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2. Relationship between SUA and CVD events 
 
Numerous studies have shown that hyperuricemia predicts an increased risk of 
cardiovascular events and death from cardiovascular causes and from all other causes 
(Verdecchia et al. 2000; Puddu et al 2001; Hoieggen et al., 2004; Niskanen et al., 2004; 
Hakoda et al. 2005; Ioachimescu et al., 2008; Strasak et al., 2008; Chen et al., 2009), 
while others have not found such an independent association (Sakata et al., 2001; Jee et 
al., 2004; Strasak et al., 2008).  
Higher SUA concentrations have been proposed to be independently associated with 
an increased risk of developing ischemic heart disease, and a number of prospective 
studies have examined this association (Zoppini et al., 2009; Ioachimescu et al., 2008; 
Strasak et al., 2008; Chen et al., 2009, Mazza et al 2007, Meisinger 2008; Navaneethan 
2009. Okura et al 2009; Ong et al., 2010). Of these, only 1 study has documented a direct 
association with incident CVD in the general population (Puddu et al., 2001), and 2 
studies have investigated the association of SUA with cardiovascular events in patients 
(Navaneethan et al., 2009; Okura et al 2009). 
Although positive associations have been previously reported between SUA levels 
and CVD risk, some of these associations failed to show statistical significance after 
adjusting for additional confounders. In addition, the Fremantle Diabetes study showed 
that baseline SUA levels were not independently associated with either CVD mortality or 
all- cause death after adjustment for other risk factors in a community-based cohort of 
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patients with type 2 diabetes who were followed for a mean of >10 years (Ong et al., 
2010).  
Most of these reports did not fully adjust for other biochemical variables such as 
renal function, glucose, use of medication and measures of lipid profiles. Controlling for 
these factors is important since higher uric acid levels may be a comorbidity of alterations 
in these other metabolic variables.  
Famous studies such as the Atherosclerosis Risk in Communities study (Moriarity et 
al., 2000; Hozawa et al., 2006) and the Framingham Study (Ioachimescu et al., 2008; 
Culleton et al., 1999) were not consistent with SUA being an independent risk factor for 
CHD. Other studies have not shown elevated SUA levels to be an independent predictor 
of CHD mortality. The NHANES I Epidemiologic Follow-up Study (Fang et al., 2000), 
reported that the association of serum uric acid levels after controlling for potential risk 
factors with cardiovascular mortality persisted. Even among subjects with low 
cardiovascular risk (ie, those without an increased cholesterol level, hypertension, or 
diabetes), they found that increased serum uric acid levels were a predictor of 
cardiovascular mortality. This association is unlikely to be confounded by other factors in 
these low-risk subjects (Fang et al., 2000). 
Hyperuricemia in this study did not significantly contribute to coronary disease-
related mortality. However, hyperuricemia was found to affect ischemic stroke in the 
Rotterdam study (Bos et al., 2006). The discrepancy between the findings of the 
Rotterdam study and the present study may be due to the relatively low risk of CHD and 
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hemorrhagic stroke in Koreans (Song et al., 2001; Song et al., 2004). .Additionally, a lack 
of statistical significance can be attributable to small sample size and insufficient power. 
Adjusting for all variables and analyzing the incidence of all cardiovascular events in 
participants with hyperuricemia stratified by sex, our study showed a significant positive 
relationship with CVD and ischemic heart disease. In our study with a large sample size, 
the association between high SUA levels and CVD, particularly ischemic heart disease, 
was statistically significant after multivariate adjustment, and women with hyperuricemia 
had a 2.09-fold increase in the risk of hard CHD (95% CI, 1.27-3.42; data not shown). 
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3. Gender differences in SUA and CVD events 
 
In the KHS, we found that there were gender differences in the association between 
SUA levels and stroke. In particular, a unique finding from the current study is that the 
relationships between SUA and the incidence of various types of CVD, particularly stroke, 
were different in women according to menopausal status. Furthermore, in our subgroup 
analysis results comparing menopausal and non-menopausal women, we found evidence 
of a dose-response association between SUA level and CVD events in pre-menopausal 
group. However, we found no significant association between the risk of CVD events and 
the SUA level among the menopausal group.  
Previous studies showed that the SUA level associated with the development of 
hypertension or cardiovascular mortality was significantly higher in women than in men 
(Zhang et al., 2009; Freedman et al., 1995; Zhang et al., 2016). The relationship of uric 
acid with cardiovascular events is particularly strong, in patients at high risk for heart 
disease and in women (Baker et al., 2005). 
Recent meta-analyses have demonstrated that hyperuricemia increased the risk of 
CHD events, particularly cardiovascular mortality in women, and that the risk of 
mortality was greater in women than in men (Kim et al., 2010; Braga et al., 2016; Zuo et 
al., 2016; Li et al., 2016). However, another meta-analysis showed that elevated SUA 
levels appeared to significantly increase the risk of all-cause mortality in men, not in 
women (Zhao et al., 2013).  
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In general, women usually have lower SUA levels than men. The association 
between SUA and CVD events in the general population is reported to be stronger in 
women than in men. This reason for this is that men are subject to other risk factors that 
more significantly influence mortality from CVD (Kawabe et al., 2016). However, the 
mechanisms that cause SUA to be less strongly related to CVD events in men than 
women remain uncertain.  
Previous studies have showed a strong association between SUA level and 
cardiovascular mortality after adjustment for menopausal status in healthy women (Fang 
et al., 2000; Strasak et al., 2008). Interestingly, in our study, although increasing SUA 
level after menopause might have influenced the outcome, elevated SUA appeared to 
have significantly increased the risk of all CVD events in premenopausal women, but not 
in postmenopausal women. The changing level of serum uric acid concentration in 
women at menopause suggests an interaction with sex hormones (Fang et al., 2000; 
Levine et al., 1989). Hyperuricemia in women could possibly be a hallmark of escape 
from estrogen protection and this phenomenon may possibly be related to estrogen levels 
(Zhang et al., 2016).   
According to a study using National Health and Nutrition Examination Survey-I data 
(Fang et al., 2000), elevated SUA levels in women were associated with higher 
cardiovascular risk than in men. This finding of a difference in the relationship between 
SUA level and CVD between men and women is similar to the findings of our study. The 
cardioprotective role of estrogen helps to explain why women, have an overall lower risk, 
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of ischemic heart disease. However, in menopausal women, men, and those with 
metabolic risk factors, a dose-response relationship was not found in stroke incidence 
according to SUA levels. The presence of low SUA levels in women may be explained 
because the secretion of uric acid is maintained in the kidney, while resorption in the renal 
tubule degrades due to female hormones and female sex hormones in postmenopausal 
women (Sumino et al., 1999).  
Differences in age, sex, and other baseline characteristics of the study, as well as 
differences in the design of the analyses may explain these disparate conclusions. Another 
factor may be that in previous analyses of CVD, there was no systematic comparison of 
the effects of SUA levels across a mild range of CVD events between the sexes. Changes 
in the SUA level according to menopausal status suggest that there is an interaction with 
sex hormones, but, this remains a matter for further research.  
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4. Mechanism of uric acid-induced CVD events  
 
High levels of uric acid, produced during the breakdown of purine, a substance 
found in many foods, have traditionally been implicated in the development of gout, 
kidney stones, and kidney failure. Given its correlations with hypertension, inflammation, 
endothelial dysfunction, insulin resistance, dyslipidemia, and obesity, a role for uric acid 
as a risk factor for CVD has recently been suggested, but the evidence is discordant 
(Zoppini, 2009).  
In recent decades, hyperuricemia has been strongly associated with peripheral, 
carotid, and coronary vascular disease, with the development of stroke, with preeclampsia, 
and with vascular dementia (Feig et al., 2008). Therefore, epidemiological studies have 
reported that multiple lines of evidence link SUA levels to metabolic risk factors. 
Although the role that elevated SUA plays in vascular disease and renal disease 
development and mortality remains unclear, the evidence suggests the following possible 
mechanisms.  
Hyperuricemia may induce endothelial dysfunction, which is predicted to promote 
the early development of atherosclerosis and precede plaque formation (Higgins et al., 
2012). The deposition of urate crystals on the vessel walls could cause an inflammatory 
reaction, then directly injure the vascular intima and ultimately activate the platelet and 
blood coagulation system. Additionally, high SUA levels also promote thrombosis and 
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activate monocyte chemotactic protein-1, an important chemokine involved in 
atherosclerosis (Baker et al., 2005, Zuo et al., 2016). 
Previous studies have shown that uric acid is an antioxidant that may prevent stress-
induced cell transformations and oxidant-induced cardiac and renal toxicity (Johnson et 
al., 2003). Increased serum concentrations of uric acid in the blood vessels may decrease 
the activity of nitric oxide and antioxidant substances in the blood vessels by degrading 
the function of vascular smooth muscle and endothelial cells. Thus, platelet aggregation 
and adhesion have been found to contribute to the development of cardiovascular disease 
(Johnson et al., 2003; Alderman et al., 2004).  
Several potential pathophysiological mechanisms have been summarized, including 
the enhancement of lipid peroxidation and platelet adhesiveness, stimulation of vascular 
smooth cell proliferation, vascular inflammation, damage to endothelial cells, the 
aggregation of erythrocytes, and the acceleration of atherosclerosis (Carmelinda et al., 
2006; Kanellis et al. 2005; Li et al., 2016; Waring et al., 2003; Montalcini et al., 2007; 
Sloop et al., 2016, Zhong et al., 2017). 
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5. Causal inference in Mendelian randomization study 
 
Mendelian randomization (MR) is a study design in which genetic variants are 
employed as instrumental variables for estimating the unconfounded effect of an exposure 
on CVD (Timpson et al., 2012).  
Although common genetic variants typically have only small effects on complex 
diseases, the combined use of multiple variants as instruments increases the statistical 
power to detect associations between exposures and outcomes (Palmer et al., 2013; 
Burgess et al., 2014; Burgress et al., 2015). Because MR studies make use of the random 
assortment of alleles at meiosis, their estimates are much less vulnerable to confounding 
than observational epidemiologic studies.  
Furthermore, because allele assignment at meiosis precedes the onset of CHD, MR 
studies are not prone to reverse causation. Finally, MR studies describe the effect of 
lifetime exposure to an allele, whereas randomized controlled trials assess the effect of an 
intervention, generally for less than a decade. For these reasons, when suitable genetic 
variants are available, MR studies can provide evidence in support of a causal association 
between exposures and outcomes (Ahmad et al., 2015).  
The current study raised doubts about the etiological relevance of SUA in 
cardiovascular and metabolic diseases as suggested by prior epidemiological and model 
systems studies, which may have observed associations between increased uric acid 
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levels and higher risks of metabolic diseases due to residual confounding or reverse 
causality. 
Although elevated SUA levels have been associated with an increased risk of 
metabolic diseases, a causal link has not been established. The results of a large MR study 
suggest that lowering SUA levels may not translate into reductions in the risk of coronary 
heart disease or ischemic stroke (Keenan et al., 2016).  
In the last few years, several MR studies have provided no evidence for a causal role 
for SUA affecting metabolic risk factors or the incidence of ischemic heart disease (Table 
5). However, a recent study documented results from multivariate and Egger MR analyses, 
which account for pleiotropy, and both analyses provided weak evidence for a causal 
association between urate and coronary heart disease. Therefore, these data suggest that 
the observed association between plasma urate and coronary heart disease is probably 
affected by confounding by risk factors such as blood pressure, LDL cholesterol, HDL 
cholesterol, and triglycerides (White et al., 2016).  
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Table 5. Overview of previously performed Mendelian randomization studies of uric acid, metabolic risk factor and 
cardiovascular disease. 
No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
Metabolic risk factors 
1 Yang,  2010 
CHARGE 
Cohorts  
  
Yang, 2010
N=28,283, 
European  
Genetic score: 
SLC22A11, GCKR,  
INHBC, RREB1,  
PDZK1, SLC2A9,  
ABCG2, SLC17A1 
Fasting 
glucose 
β -0.06 (95%CI: -
0.13,0.02)mmol/L 
Per 100 µmol/L 
urate 
Uric acid has no 
causal effect on 
fasting glucose. 
2 Pfister, 2011 
Cambridg-
eshire, 
ADDITIO
N-Ely and 
Norfolk 
Diabetes  
N=16,064, 
with 7,504 
type 2 diabetes
(T2DM)  
cases 
Genetic score: 
PDZK1, LRRC16A,  
SLC22A12, 
SLC16A9,  
SLC22A11, 
SLC17A1,  
ABCG2, SLC2A9 
T2DM 
Odds ratio 0.99 
(95% CI: 0.94-
1.04) Per genetic 
score tertile. 
Uric acid has no 
causal effect on 
type 2 diabetes. 
3 Parsa,  2012 
Hereditary 
and 
Phenotype 
Interven-
tion Heart 
Study  
N=516,  
European  SLC2A9 
Systolic blood 
pressure  
Diastolic 
blood  
pressure 
Systolic blood 
pressure: β 2.2 
(SE: 0.79) mmHg 
Diastolic blood 
pressure: β 0.42 
(0.5) mmHg per 1 
mg/dL change in 
uric acid. 
Uric acid causally 
decreases systolic 
blood pressure, but 
not diastolic blood  
pressure 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
4 Oikonen, 2012 
Cardiovascu-
lar Risk in 
Young Finns 
study  
  
N=1,985,  
European  SLC2A9 
Body mass 
index (BMI) 
Carotid intima 
media 
thickness 
Carotid intima media 
thickness: β <0.0001 
mm, P-value 0.99 
among men. BMI: β 
0.04 kg/m2, P-value 
0.82 among men and β 
0.07 kg/m2, P-value 
0.57 among women 
per standard deviation 
(SD) increase in uric 
acid. 
Uric acid has no 
causal effect on 
BMI or 
atherosclerosis 
5 Lyngdoh, 2012 CoLaus study 
N= 6,184,  
European  SLC2A9 
Weight  
Fat mass  
BMI  
Waist 
circumference
Weight: β 0.01 (95% 
CI, -0.12 to  0.14) kg 
Fat mass: β 0.05 
(95%CI, -0.10 to 0.19) 
kg  
Body mass index: β 
0.01 (95% CI,   -0.16 to 
0.14)kg/m2  
Waist circumference     
β 0.08 (95%CI, -0.05 to 
0.21)cm per SD 
increase in uric acid. 
Uric acid is not 
causally related to 
measures of 
adiposity 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
6 
Mallam-
aci,  
2014 
Mallamaci,  N= 459, European  SLC2A9 
Systolic blood 
pressure  
Diastolic 
blood  
pressure 
Higher mean 
clinic systolic 
blood pressure 
among TT 
individuals.   
No difference in 
mean diastolic 
blood pressure. 
Uric acid causally 
increases clinic 
systolic blood 
pressure, but not 
diastolic blood 
pressure. 
7 Rasheed, 2014 
Atheroscleros
is Risk in 
Communities 
and 
Framingham 
Heart  
N= 8,208,  
European  
Genetic score  
of SLC2A9, ABCG2, 
SLC17A1, 
SLC22A11,  
SLC22A12 
Triglycerides 
β -1.01 (standard 
error: 0.80) 
mmol/L per unit 
change in uric 
acid. 
Uric acid has no 
causal effect on 
triglycerides. 
8 Sedaghat 2014 
Rotterdam 
study  
N= 5,791,  
European  
Genetic score of 30 
variants in loci listed 
in Köttgen et al 
Systolic blood 
pressure  
Diastolic 
blood pressure
Systolic blood 
pressure: β -0.75 
(95% CI, -1.31 to 
-0.19)mmHg 
Diastolic blood 
pressure: β -0.92 
(95% CI, -1.62 to 
-0.23)mmHg per 
SD increase in 
genetic score. 
Uric acid causally 
decreases systolic 
blood pressure and 
diastolic blood 
pressure. 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
Metabolic syndrome and Cardiovascular disease 
9 McKeigue 2010 
ORCADES 
study  
N=706,  
European  SLC2A9 
Metabolic 
syndrome 
Causal effect 
parameter βx :      
-1.25 (95% CI,      
-2.91 to 0.05) 
Uric acid has no 
causal effect on 
metabolic 
syndrome. 
10 Dai,  2013 
Dongfeng-
Tongji Cohort 
study  
N= 23,345,  
Asian  
Genetic score  
of SLC2A9,  
ABCG2 
Metabolic 
syndrome 
Odds Ratio 1.03 
(95% CI, 0.98 to 
1.09) Per uric acid 
increasing allele 
in the risk score 
Uric acid is not 
causally related to 
metabolic 
syndrome. 
11 Palmer, 2013 
Copenhagen 
General 
Population 
Study and 
Copenhagen 
City Heart 
Study 
N=68,674, 
with 7,172  
ischemic 
heart 
disease 
events,  
European  
SLC2A9 (rs7442295) 
 
FTO(rs9939609),  
MC4R (rs17782313), 
TMEM18 
(rs6548238) for body 
mass index 
Ischemic heart 
disease  
Systolic blood 
pressure  
Diastolic 
blood pressure
Ischemic heart 
disease: hazard 
ratio: 0.93 (95% 
CI: 0.79-1.09) 
Systolic blood 
pressure: β 0.65 
mm Hg (95% CI: 
−0.54 to 1.85)  
Diastolic blood 
pressure: β 0.63 
mmHg (95% CI: 
−0.04 to 1.29) per 
SD increase in 
uric acid. 
Uric acid has no 
causal effect on 
ischemic heart 
disease, systolic 
blood pressure and 
diastolic blood 
pressure. 
However, evidence 
supports a causal 
effect between body 
mass index and uric 
acid level and 
hyperuricemia. 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
12 
Testa  
et al. 
2015 
MAURO 
Study 
GHS 
(Gargano 
Heart Study) 
TVAS (Tor 
Vergata 
Atheroscleros
is Study) 
N= 1,227 
high risk 
patients 
 
MAURO: 
755 
Chronic 
kidney 
disease;  
GHS: 353 
type 2 
diabetes 
and 
coronary 
heart 
disease; 
TVAS: 119 
myocardial 
infarctions 
 
Italian 
GLUT9 (rs734553) 
urate transporter gene
Cardiovascul-
ar death, and 
non-fatal 
myocardial 
infarction and 
stroke 
The meta-
analytical 
estimate (total 
number of 
patients, 
n=1,227; total 
cardiovascular 
events, n=222) of 
the hazard ratio 
(HR) for the 
combined end-
point in TT/GT 
patient was twice 
higher (pooled 
HR: 2.04; 95% 
CI, 1.11-3.75; P= 
0.02) than in GG 
homozygotes. 
The T allele of the 
rs734553 
polymorphism in 
the GLUT9 gene 
predicts a doubling 
in the risk for 
incident 
cardiovascular 
events in patients at 
high cardiovascular 
risk.  
The findings in this 
study are 
compatible with the 
hypothesis of a 
causal role of 
hyperuricemia in 
cardiovascular 
disease in high risk 
conditions. 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
13 Kleber et al., 2015, 
Ludwigsha-
fen Risk and 
Cardiovascu-
lar Health 
Study 
N= 3,316 
South-
western 
 
Germany 
GRS 
Non-pleiotropic 
SNPs 
SLC2A9, NRXN2, 
UBE2Q2, A1CF, 
MAF, SFMBT1, 
HLF, BAZ1B, STC1, 
NF4G, ATXN2, 
3GNT4, GF1R, 
NFAT5 
Pleiotropic SNPs 
ABCG2, GCKR, 
TMEM171, 
SLC16A9, INHBB, 
RREB1, SLC17A1, 
PDZK1, INHBC, 
SLC22A11, 
ACVR1BL1, 
VEGFA, TRIM46, 
PRKAG2 
Cardiovascul-
ar death  
sudden cardiac 
death 
In a multivariate 
model adjusted 
for factors 
including 
medication, 
causal HRs 
corresponding to 
each 1mg/dL 
increase in 
genetically 
predicted uric 
acid concentration 
were significant 
for cardiovascular 
death (HR, 1.77; 
95% CI, 1.12 to 
2.81) and 
sudden cardiac 
death (HR, 2.41; 
95% CI, 1.16 to 
5.00) 
High uric acid is 
causally related to 
adverse 
cardiovascular 
outcomes, 
especially sudden 
cardiac death. 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
14 
Keenan 
et al.  
2016 
PROMIS 
(Pakistan 
Risk of 
Myocardial 
Infarction 
Study) 
 
N= 71,501,  
T2DM 
(26,488/ 
83,964),  
Coronary 
heart disease 
(CHD) 
(54,501/ 
68,275), 
Ischemic 
stroke 
(14,779/ 
67,312) 
Heart Failure 
(HF) (4,526/ 
18,400) 
STC1, ACVR1B-
L1, PRKAG2, 
TMEM171, HLF, 
HNF4G, SFMBT1 
NRXN2, TRIM46, 
A1CF, PDZK1, 
RREB1, 
SLC22A11, 
SLC2A9 
T2DM, CHD, 
ischemic 
stroke, or HF 
A 1 SD increase 
in serum urate 
levels due to the 
genetic score was 
associated with 
increased risk of 
gout (odds ratio: 
5.84; 95% CI: 
4.56 to 7.49) 
Evidence from this 
study does not 
support a causal 
role of circulating 
serum urate levels 
in T2DM, CHD, 
ischemic stroke, or 
HF.  
Decreasing serum 
urate levels may not 
translate into risk 
reductions for 
metabolic 
conditions. 
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No Author, Year Study Participants
Uric acid- 
associated loci 
Main 
outcome(s) Causal estimate Conclusions 
15 White et al, 2016 
MAGIC (Meta-
Analyses of 
Glucose and 
Insulin-related 
traits 
Consortium), 
GIANT 
(Genetic 
Investigation of 
AN thropometric 
Traits), 
DIAGRAM 
(DIAbetes 
Genetics 
Replication And 
Metaanalysis) 
GLGC (Global 
Lipids Genetic 
Consortium),  
ICBP 
(International 
Consortium for 
Blood Pressure) 
Meta-analysis 
of 17 
prospective 
observational 
studies 
(166,486 
individuals; 
9,784 
coronary 
heart disease 
events) 
 
Egger 
mendelian 
randomisati-
on analysis 
(58 studies; 
198,598 
individuals;  
65,877 
events) 
31 urate-
associated SNPs 
PDZK1, GCKR, 
SLC2A9, ABCG2, 
RREB1, 
SLC17A1/SLC17A3 
SLC16A9, SLC22A11, 
NRXN2/SLC22A12, 
INHBC/INHBE, 
TRIM46/PKLR, 
INHBB, 
SFMBT1/MUSTN1, 
TMEM171, VEGFA, 
BAZ1B/MLXIPL, 
PRKAG2, HNF4G, 
A1CF/ASAH2, 
OVOL1/LTBP3, 
ATXN2/PTPN11, 
UBE2Q2/NRG4, 
IGF1R, NFAT5, MAF, 
HLF, 
LRRC16A/LRRC16A, 
ORC4L/ACVR2A, 
STC1, 
BCAS3/C17orf82, 
QRICH2/PRPSAP1 
Coronary 
heart disease 
The 
corresponding 
odds ratio 
estimates from the 
conventional, 
multivariable 
adjusted, and 
Egger Mendelian 
randomisation 
analysis were 
1·18 (95% CI, 
1·08–1·29), 1·10 
(1·00–1·22), and 
1·05 (0·92–1·20), 
respectively, per 1 
SD increment in 
plasma urate. 
Genetic evidence 
based on 
conventional and 
novel Mendelian 
randomization 
approaches suggest 
a modest, if any, 
causal effect of 
plasma urate 
concentration in the 
development of 
coronary heart 
disease 
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6. Study limitations and strengths 
 
This study has some limitations. As in most studies, we did not consider changes in 
SUA levels, which were determined from a single measurement. In addition, this study 
was carried out in health promotion centers, which may not be representative of the 
general population. At the time of data collection, some degree of recall bias may have 
been present regarding subjects’ history of hypertension, diabetes, and frequency of 
cigarette and alcohol consumption. The effect of these factors as confounders on the 
independent predictive power of SUA levels on CVD events was considered minimal, in 
accordance with previous population-based studies.  
The strength of this study is that it included a large sample size, a relatively long 
duration of follow-up and mostly accurate outcomes of cardiovascular events from death 
certificate data and hospitalization records. In addition, it has also been shown that 
hyperuricemia is associated with the development of all CVD forms, including ischemic 
and hemorrhagic stroke, although its effects on the severity of heart disease have not been 
previously reported to the best of our knowledge. Few studies have reported on the 
association between SUA and stroke in the general population and none of these studies 
divided stroke into ischemic and hemorrhagic.  
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VI. CONCLUSIONS  
  
In conclusion, SUA was found to be an independent risk marker for atherosclerotic 
CVD in the general population without metabolic risk factors. SUA may be an important 
and clinically useful marker that can be used to predict ischemic heart disease, 
particularly in healthy men and women without major risk factors. Asymptomatic 
hyperuricemia was associated with the incidence of atherosclerotic CVD in the KHS.  
Our study also demonstrated a dose-response effect of increased SUA levels on 
ischemic heart disease, particularly in women without metabolic risk factors. Most 
importantly, SUA levels were an independent predictor of ischemic heart disease in both 
men and women without diabetes. Further research is needed to broadly evaluate the 
causal effects of multiple biomarkers on cardiovascular disease and metabolic risk traits 
using data from large-scale cohorts or genome-wide association studies including many 
different genetic variants. 
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APPENDIX  
 
■   Hazard ratio ,   –––––   95% CI 
Figure A1. Hazard ratios for ischemic heart disease incidence to subgroup on the 
basis of uric acid in men. 
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■   Hazard ratio ,   –––––   95% CI 
Figure A2. Hazard ratios for ischemic heart disease incidence to subgroup on the 
basis of uric acid in women. 
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대사성 위험요인에 따른 혈청요산과 심혈관 질환: 한국인 심장병 연구 
  
연세대학교 대학원 보건학과  
박 은 정  
배경 및 목적  
고혈압, 염증, 내피기능의 부전, 인슐린 저항성, 비만 등과 관련성이 있으며, 
최근 대규모 연구에서 고요산혈증이 심혈관 질환 발생의 독립적 위험인자로 
보고하였으나, 연구결과 간에 차이를 보였다. 따라서, 이 연구의 목적은 대사성 
위험요인의 유무에 따라, 대규모 한국인 일반인구집단에서 혈청요산수치와 
심혈관 질환의 발생위험과의 관련성을 확인하는 것이다. 
  
연구 방법  
1996 부터 2004 년까지 전국 18 지점의 건강검진센터를 방문한 465,233 명의 
한국인 심장병연구에 등록된 성인을 대상으로 과거 심혈관 질환이 없고 혈중 
요산수치를 측정한 322,467 명을 대상으로 분석하였다. 대사성 위험요인의 정의는 
허리둘레를 제외하고 수정된 NCEP-ATP III 기준을 정의하였으며, 혈중 요산수치의 
5 분위수에 따라, Cox 비례위험모형을 사용하여 심혈관질환 발생 위험을 산출하였다. 
81  
  
  
  
연구 결과  
총 추적관찰기간은 9.5 년 동안 잠재적 교란요인을 보정한 후, 혈증요산수치와 
심혈관질환 발생(27,009 건)과의 관련성을 평가하였다. Cox 비례위험모형을 
이용한 분석결과로는 혈청요산수치가 가장 높은 남자그룹(>6.8mg/dl 이상)과 
여자그룹(4.8mg/dl 이상)이 심혈관 질환과 허혈성 심장질환의 발생위험이 
증가하였다. 잠재적 위험요인들을 보정한 고요산혈증의 심혈관질환 위험은 
정상수치에 비해 남성이 1.20 배(95 % CI, 1.12-1.30), 여성이 1.44 배(95 % 
CI, 1.27-1.63) 높았다. 기존의 대사성 위험인자별로 층화하여 허혈성 
심장질환과의 관련성을 분석한 결과, 당뇨병이 없는 대상자의 하위 그룹분석에서 
허혈성 심장질환의 발생위험은 남자가 1.24 배(95 % CI; 1.11-1.38), 여자는 
1.52 배(95 % CI; 1.29-1.78) 높았다. 
 
결론  
높은 혈청요산수치는 심혈관질환 중에서 허혈성 심장병 발생과의 관련성은 기존 
연구와 일치하였으며, 대사성 위험요인이 없는 성인에서 고요산혈증은 허혈성 심장병 
위험이 높았고, 특히 남성보다 여성에서 더 유의하였다. 혈청요산수치와 심혈관계 
질환의 원인인과관계를 확인하기 위하여 심혈관질환 및 대사위험인자에 대한 
바이오마커와 다양한 유전변이들을 광범위하게 평가하는 추가 연구들이 필요하다.  
 
핵심어: 요산, 심뇌혈관질환, 대사성 위험요인, 코호트 연구 
